The Medicines Company Settles Angiomax Patent Litigation With Sun

The Medicines Company

today announced that it has settled its litigation with Sun Pharmaceutical Industries Ltd. (Sun Pharma) and certain of its subsidiaries relating to MDCO's U.S. Patent No. 7,582,727 and U.S. Patent No. 7,598,343 covering Angiomax® (bivalirudin). The patents are listed in the Orange Book and expire on July 27, 2028. As a result of the settlement, MDCO will permit a Sun Pharma subsidiary to market a generic bivalirudin product in the United States on June 30, 2019, or earlier in certain limited circumstances. This settlement validates MDCO's patents while allowing a Sun Pharma subsidiary to enter the market with its generic product. Glenn Sblendorio, President and Chief Financial Officer of The Medicines Company stated, "This settlement further confirms the strength of our Angiomax patents and, we believe, is a common sense approach to resolving this litigation." The other terms of the agreement are confidential. The agreement will be submitted to the applicable governmental agencies for review.